introducing Helix Cardia
A Unique Device Approach to Treating Advanced Heart Failure
HelixCardia™ is based on the concept of helically arranged myocardial fibers that connect cardiac apex to its base, providing a “positive-displacement” in systole and a “suction” during diastole. HelixCardia™ does not have any direct contact with circulating blood, and thus requires no blood-thinning medications (eliminating the risk of stroke and bleeding). Once implanted, the heart remains functionally intact. HelixCardia™ is percutaneously implantable through a small incision in the rib space, which benefits heart failure patients in stage D who may not tolerate a major open-chest surgery.
Burden of Heart Failure
Heart failure (HF) affects six million individuals costing over $30 billion annually in the U.S. Among these, between 150,000 to 250,000, reach stage D (end stage) failure, but only about 6,000 receive a heart transplant or a ventricular assist device (VAD). Co-morbidities and limited donor supply are the main reasons preventing these patients from receiving a heart transplant. Additionally, most of these patients are either too ill to undergo major cardiac surgery or do not find current VADs acceptable due to the risk of long-term complications (stroke, bleeding, infections). Thus, the only current option for most of the HF patients in stage D is palliative care.
How does HelixCardia™ work?
The National Institutes of Health has awarded ValVention Inc. $350,000 to study the effectiveness of FoldaValve™ transcatheter aortic valve replacement (TAVR) system. The NIH funding will support a project to test the hypothesis that the patented sheathed inverse folding mechanism of the FoldaValve™ technology is more durable and protective of the valve’s structural integrity when compared with standard crimping methods…
Transcatheter aortic valve replacement (TAVR) is an essential alternative to surgical aortic valve replacement (SAVR) in elderly patients with aortic valve stenosis. At the current pace, TAVR procedures are expected to increase twofold from ~163,000 in 2020 to ~289,000 in 2025, and the number of patients with severe aortic stenosis is anticipated to rise to 3.5M by 2050. ValVention Inc…